PHASQ PhaseBio (PNK) drops 99% on Jan 15 2026: top loser, cash runway risk
PHASQ stock plunged 99.00% in market hours on Jan 15 2026, closing near USD 1e-06 on the PNK exchange in the United States. Volume was light at 2,500 shares versus an average of 22,310, and the one-day move left the stock well below its 50-day average of 0.000236 and 200-day average of 0.000666. Investors should view this as a top losers signal driven by bankruptcy-era liabilities, thin liquidity, and continuing clinical and funding uncertainty for PhaseBio Pharmaceuticals, Inc. (PHASQ)
PHASQ stock price action and market context
PHASQ stock fell 99.00% intraday to USD 1e-06 on Jan 15 2026, marking one of the largest single-session percentage declines in the security’s recent history. Trading volume was 2,500 shares, which is 0.11x of the average volume of 22,310, indicating limited liquidity and outsized impact from small trades.
Drivers behind the drop and PHASQ news
The primary drivers for the decline are legacy Chapter 11 restructuring outcomes and lingering doubt about funding for PhaseBio’s lead assets, notably bentracimab (PB2452). There were no major new clinical readouts on Jan 15 2026; the move appears driven by market re-pricing and low float, not fresh positive catalysts. For company background see the official site source.
PHASQ stock financials and valuation snapshot
PhaseBio reports EPS of -2.14 and a negative PE calculation; book value per share stands at -3.16 and cash per share is 1.42 on trailing metrics. Price averages of 0.000236 (50-day) and 0.000666 (200-day) highlight a long-term downtrend. The company is in the Biotechnology industry within Healthcare and shows severe valuation stress given enterprise value metrics and negative earnings.
Technicals, liquidity and trading risk for PHASQ stock
Technically, PHASQ stock is below all moving averages and year low of 0.000001, with a year high at 0.03990, indicating extreme volatility and historical wide price range. Average daily volume of 22,310 versus current volume 2,500 signals episodic trading and high execution risk. Short-term traders face wide spreads and limited fills on PNK in USD.
Meyka AI grade and PHASQ forecast
Meyka AI rates PHASQ with a score out of 100: Score: 59.03 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects USD 0.00 over the 12-month horizon versus the current price of USD 1e-06, implying an expected downside of -100.00%. Forecasts are model-based projections and not guarantees. For more context see our internal coverage Meyka PHASQ page.
Risks, opportunities and PHASQ outlook
Main risks include insolvency proceedings, dilution from future financings, and failure to commercialize bentracimab or PB1046. Upside would require successful resolution of restructuring, fresh capital, or positive Phase III data for PB2452. Given the balance sheet and historical filings, the path to recovery is high risk and low probability without clear external funding.
Final Thoughts
PHASQ stock is a clear market hours top loser on Jan 15 2026 after a 99.00% drop to USD 1e-06 on the PNK exchange in the United States. The move reflects bankruptcy-era balance sheet strain, crushed liquidity, and ongoing clinical and financing uncertainty for PhaseBio Pharmaceuticals, Inc. (PHASQ). Meyka AI’s forecast model projects USD 0.00 over 12 months, implying an expected downside of -100.00% from the current quoted price of USD 1e-06; forecasts are model-based and not guarantees. Realistic price targets for scenario analysis: bear USD 0.000000 (implied -100.00%), base USD 0.00050 (implied +49,900.00%), and bull USD 0.02000 (implied +1,999,900.00%) — each assumes different outcomes on restructuring and clinical progress. Given EPS -2.14, negative book value, and light liquidity, the stock is best treated as highly speculative. Use strict position sizing and confirm any corporate updates on the company site or regulatory filings before acting. For company filings and public statements see the corporate site source and official Twitter feed source.
FAQs
What caused the PHASQ stock drop on Jan 15 2026?
The drop was driven by restructuring-related uncertainty, thin liquidity and lack of new clinical catalysts, pushing PHASQ stock down about 99.00% to USD 1e-06 on PNK during market hours.
What is Meyka AI’s view on PHASQ stock?
Meyka AI rates PHASQ with a score of 59.03 (C+, Suggestion: HOLD) and projects USD 0.00 over 12 months; this is a model projection and not investment advice.
Are there price targets for PHASQ stock?
Scenario targets include bear USD 0.000000, base USD 0.00050 and bull USD 0.02000; implied returns vary widely and hinge on restructuring and clinical outcomes.
How liquid is PHASQ stock for trading?
Liquidity is low: current volume was 2,500 versus an average of 22,310 shares, creating high execution risk and wide spreads on PNK in USD for PHASQ stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
